{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-191942","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2023-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.721755+00:00","generated_at":"2026-06-13T04:38:57.299750+00:00","sec_items":["1.01","3.02","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Heron Therapeutics raises $30M equity, cuts 25% workforce, targets profitability late 2024","bullets":["Private placement of 20.7M shares at $1.37 and pre-funded warrants for up to 1.16M shares; gross proceeds ~$30M.","Cost reduction plan: $75M cash savings through 2025 including $45M operational savings; 25% employee reduction; $5.9M charge in 2023.","COO David Szekeres resigned July 20, 2023 by mutual agreement; entitled to severance under amended employment agreement.","Company states financing may be last equity raise before reaching cash flow positivity; aims for profitability late 2024.","Waiver granted to Rubric and Velan under Cooperation Agreement allowing beneficial ownership above 15%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-191942","json":"https://secwatch.observer/filing/0001193125-23-191942.json","markdown":"https://secwatch.observer/filing/0001193125-23-191942.md","text":"https://secwatch.observer/filing/0001193125-23-191942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000119312523191942/0001193125-23-191942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000119312523191942/d527822d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T04:38:57.299750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26db59aa98","claim":"David Szekeres resigned as Executive Vice President, Chief Operating Officer at HERON THERAPEUTICS, INC. /DE/.","evidence_excerpt":"On July 20, 2023, by mutual agreement, David Szekeres resigned as Executive Vice President, Chief Operating Officer of the Company, effective July 20, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000119312523191942/0001193125-23-191942-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President, Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"6ed7383cad772f58a9f4154a27816a4b2da45359","claim":"HERON THERAPEUTICS, INC. /DE/ entered into Securities Purchase Agreement with Rubric Capital Management LP, Velan Capital, Clearline Capital and Hercules Capital, Inc. valued at approximately $30.0 million (effective 2023-07-21).","evidence_excerpt":"On July 21, 2023, Heron Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) for a private placement (the “ Private Placement ”) with Rubric Capital Management LP (“ Rubric ”), Velan Capital (“ Velan ”), Clearline Capital and Hercules Capital, Inc. (each a “ Purchaser ”, and collectively, the “ Purchasers ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000119312523191942/0001193125-23-191942-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Rubric Capital Management LP, Velan Capital, Clearline Capital and Hercules Capital, Inc."},{"label":"Value","value":"approximately $30.0 million"},{"label":"Effective","value":"2023-07-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}